Journal of Pharmaceutical Care & Health Systems
Open Access
ISSN: 2376-0419
ISSN: 2376-0419
Sweta Patel, Jean Nappi and Amy Thompson
Abstract Purpose: The purpose of the study was to assess the quality of anticoagulation with warfarin in patients with non-valvular AF who were managed exclusively in pharmacy run anticoagulation clinics and to evaluate whether these patients would be expected to have the same efficacy and safety profiles as those patients in the RE-LY, ROCKET AF, and ARISTOTLE trials. Methods: This was a retrospective study of 146 patients in 3 pharmacy run anticoagulation clinics who were initiated on anticoagulation with warfarin therapy to prevent stroke associated with atrial fibrillation. International Normalized Ratio (INR) values were collected over a 1-year period and the quality of management was expressed as time in therapeutic range (TTR) calculated by Rosendaal’s linear interpolation method. Results: Forty-six patients from university internal medicine (UIM) clinic, 9 patients from family medicine (FM) clinic, and 91 patients from pharmacotherapy (PCT) clinic were studied. During the 1-year period, the overall mean TTR was 61.1%. The mean TTR in the UIM clinic, the FM clinic, and the PCT clinic was 60.1%, 62.5%, and 61.5%, respectively. Conclusion: The quality of anticoagulation with warfarin, as assessed by TTR, in the 3 pharmacy run anticoagulation clinics was similar to the mean TTR values reported for the warfarin-treated patients in the RE-LY, ROCKET-AF, and ARISTOTLE trials. The results of these studies are applicable to our patient population.